Welcome to our dedicated page for Pop Culture Group Co. SEC filings (Ticker: CPOP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Pop Culture Group鈥檚 hip-hop empire? If you鈥檙e asking 鈥淲here can I find CPOP鈥檚 quarterly earnings report 10-Q filing?鈥� or want CPOP SEC filings explained simply, you鈥檙e in the right place. This hub tracks every disclosure the moment it hits EDGAR, from CPOP insider trading Form 4 transactions to CPOP 8-K material events explained.
Stock Titan鈥檚 AI reads each document in seconds, then returns concise, context-rich notes. Need CPOP executive stock transactions Form 4 in real time? We flag them. Curious about CPOP proxy statement executive compensation? Our summaries point you straight to pay tables and option grants. Prefer plain language? The platform turns accounting jargon into actionable insights so you can focus on decisions, not page counts.
- CPOP annual report 10-K simplified 鈥� deep dive into sponsorship concentration and regulatory risk factors.
- CPOP earnings report filing analysis 鈥� quarter-over-quarter ticket-sales trends visualised instantly.
- Understanding CPOP SEC documents with AI 鈥� segment revenue, MCN growth, and liquidity metrics clarified.
Because CPOP straddles live events and digital marketing, its disclosures reveal unique signals: dependence on street-dance competitions, performance of its 70-million-fan KOL network, and sensitivity to China鈥檚 event regulations. Our expert layer links those themes to the exact pages inside each filing. Whether you鈥檙e monitoring CPOP Form 4 insider transactions real-time or comparing historical margins, this page delivers every detail鈥攚ithout drowning you in paperwork.
Service Corporation International (SCI) posted solid Q2-25 results. Revenue rose 3.0% YoY to $1.07 billion, driven by 4.5% service growth and a 28.4% jump in other revenue. Gross margin expanded 50 bp to 25.5%, lifting gross profit to $271.4 million (+5.3%). After $1.6 million in restructuring charges and $4.1 million divestiture gains, operating income reached $224.5 million (+1.6%). Net income attributable to stockholders advanced 4.0% to $122.9 million; diluted EPS improved to $0.86 from $0.81 (+6.2%).
For the first half, revenue gained 2.9% to $2.14 billion, while diluted EPS climbed 8.9% to $1.84. Cash & equivalents increased to $255.4 million (-6 month +$36.6 million) and free cash flow remained strong at $477.6 million. SCI repurchased 4.1 million shares for $325.9 million and lifted its authorization to $600 million; dividends were raised 7% to $0.32 per share. Total debt grew to $5.04 billion (net +$202.7 million YTD) as the company tapped its credit facility to fund buybacks and a new headquarters build, but leverage of 3.68脳 stays well below the 5.0脳 covenant. The preneed backlog expanded to $16.4 billion, and trust investment income added $100.8 million YTD.
Pop Culture Group Co., Ltd (Nasdaq: CPOP) has completed a Regulation S private placement. On 4 July 2025 the company signed subscription agreements with ten non-U.S. investors for the sale of 50 million Class A ordinary shares at $0.50 and 10 million Class B ordinary shares at $0.55. The transaction closed on 8 July 2025, generating gross proceeds of $30.5 million.
The newly issued shares are exempt from U.S. registration requirements because all subscribers certified that they are not "U.S. persons" under Rule 902(k) of Regulation S. Management retains sole discretion over the use of proceeds; no specific allocation was disclosed in the filing.
The company attached the forms of the Class A and Class B subscription agreements as Exhibits 10.1 and 10.2. Other than the capital raise, the Form 6-K contains no financial statements, operational updates or earnings data.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has furnished an 8-K under Item 7.01 to disclose positive interim Phase 2 results for its mRNA candidate ARCT-810, which is being developed to treat ornithine transcarbamylase (OTC) deficiency. The company states that the investigational therapy is designed to replace the OTC enzyme and restore urea-cycle function, thereby preventing hyperammonemia crises in affected patients.
- A press release detailing the data and a webcast presentation were released on 30 Jun 2025 and are attached as Exhibits 99.1 and 99.2.
- The disclosure is furnished鈥�not filed鈥攗nder Regulation FD; therefore, it carries no Section 18 liability and will not be incorporated by reference into future SEC filings.
- No financial statements, earnings figures, or transaction details are included.
The filing underscores continued progress in Arcturus鈥檚 rare-disease pipeline and may influence investor sentiment pending full Phase 2 data and eventual pivotal trials.
FAQ
What is the current stock price of Pop Culture Group Co. (CPOP)?
What is the market cap of Pop Culture Group Co. (CPOP)?
What does Pop Culture Group Co., Ltd (CPOP) specialize in?
How does Pop Culture generate revenue?
What is the company's competitive advantage?
What is the role of KOLs in Pop Culture's business model?
What challenges does Pop Culture face in its industry?
What industries does Pop Culture operate in?
How does Pop Culture leverage digital innovation?
What is Pop Culture's market positioning?
